Posted by Michael Wonder on 10 Oct 2019
Emergent BioSolutions receives EMA Prime Designation for its Chikungunya virus vaccine candidate
10 October 2019 - Emergent BioSolutions today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the CHMP of the EMA during its September meeting.
The PRIME scheme is designed to enhance support for the development of medicines that target an unmet medical need and that may offer a major therapeutic advantage over existing treatments, or benefit patients without preventative or treatment options.
The CHIKV VLP vaccine candidate is being developed for the prevention of disease caused by chikungunya virus infection, an illness that spreads through mosquito bites and for which no vaccine or treatment is available.
